-: My name is Marcus Wilson.
I'm the president of Health Core.
So we do a lot with pharmaceuticals.
A lot with bio technologies, medical devices.
Those types of technologies.
But it's not just that.
Those are sort of the clinical research arm of what we do.
There's also a lot of health services research
we do as an organization as well.
So once you know what needs
to happen in health care,
how do we actually get providers and patients
to understand that and to follow those recommendations?
And so we do a bit of our own
health services research as well.
It can go anywhere from does this drug work
as well once it comes into the real world setting
as well as it works in the clinical trial?
Does it work in certain patients,
better than it works in other patients?
So those are the clinical aspects
of it, or clinical outcomes.
We do work in health economics.
So we can say, well okay it may work a little bit better
but it costs ten times more.
So what's sort of the relative value
in that situation of option A versus option B.
And is there a way to optimize that?
And then we do a lot of work
in patient reported outcomes as well.
So it's not just about the clinical
and economic aspects, it's the humanistic side
of things as well, so we really want to know
are we addressing the issue from the patients perspective.
So we do a lot of patient reported outcomes as well.
Quality of life, patient satisfaction, things like that.
A lot of what we've been working on recently,
so we do a hundred, a hundred twenty projects
a year for a life sciences company.
We work for the FDA.
We do work for payers.
Different payers have questions as well.
A lot of our work recently
has been working with organizations like the FDA
to think to evolve the health care
evidence generation system as a whole.
Realizing that the current research infrastructure is good,
but it's not good enough to answer some of the questions
once a product comes into the marketplace.
We can answer regulatory decisions well,
the efficacy and safety.
But when the product comes into the marketplace
you've got both physicians as well as other institutions,
like hospitals and then payers
trying to understand the product from a,
what's the impact gonna be on my population,
or my patients specifically.
So we've been working a lot with the FDA
and others on evolving the system
to actually answer those questions more rapidly.
Because today you can only answer them
once a product comes on the market,
and you gradually begin to build the evidence.
It's a slow process, and it adds
to the cost of developing a product.
But we're trying to think what ways to do,
is to generate the evidence much sooner.
Perhaps as soon as when the product comes
on the market, or very rapidly afterward.
So doing it faster.
But also actually doing it at a lower price point
so it doesn't add to the cost
of the development of a product.